• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Travere Therapeutics Appoints Jula Inrig, M.D., as Chief Medical Officer

    1/4/22 4:30:00 PM ET
    $TVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TVTX alert in real time by email

    SAN DIEGO, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced the appointment of Jula Inrig, M.D., as chief medical officer, effective immediately. Dr. Inrig brings to Travere more than 15 years of expertise in medical oversight, drug development, clinical trial planning and execution and global regulatory engagement. Dr. Inrig joins the Company as it prepares for accelerated approval submissions of sparsentan for IgA nephropathy (IgAN) and focal segmental glomerulosclerosis (FSGS) in 2022, as well as the continued advancement of its pegtibatinase program in classical homocystinuria (HCU).

    "We are excited to welcome Jula to the Travere Therapeutics team," said Eric Dube, Ph.D., chief executive officer of Travere Therapeutics. "Jula has a clear passion for championing positive advancements for patients. Her demonstrated expertise in clinical development and history of successfully collaborating with regulators, healthcare providers and patient communities to develop new treatment options further strengthens our leadership team as we continue to advance our pipeline and enter a pivotal phase for Travere."

    "I am thrilled to be joining a patient-inspired company that focuses on bringing new therapeutics to people living with rare diseases," commented Dr. Inrig. "Travere is at an especially exciting inflection point on the path to potentially delivering new treatment options for patients living with rare kidney disorders, and I look forward to continuing to work with regulators and the nephrology community with the ultimate goal of providing greatly needed new advancements in care. I also look forward to bringing my experience in clinical development to the team as we advance a pipeline of potential first-in-class therapies."

    Dr. Inrig joins Travere from IQVIA where she served as Global Head of the Renal Center of Excellence. While at IQVIA, Dr. Inrig was instrumental in the design, execution and strategy of clinical trials leading to U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) approvals in autosomal dominant polycystic kidney disease (ADPKD), and diabetic kidney disease. During her tenure at IQVIA, Dr. Inrig was responsible for the execution of more than 45 clinical trials across 50 countries, enrolling over 25,000 patients, including pivotal phase 3 trials in FSGS, IgAN and lupus nephritis. In addition to her roles at IQVIA, Dr. Inrig served as an inaugural member of the board for the Kidney Health Initiative, a public-private partnership with the FDA founded with the goal of improving the development of therapies for patients with kidney disease. Dr. Inrig has also served in advisory roles for national societies and their guidelines including the American Society of Nephrology, the National Kidney Foundation, and the American Heart Association.

    Dr. Inrig is board certified in Nephrology and Internal Medicine and has served on the faculty at the University of California, Irvine, and as an adjunct in the Department of Medicine at the Duke University School of Medicine. Dr. Inrig received her M.D. from Loma Linda University and completed her Internal Medicine Residency, her Nephrology Fellowship and obtained a Masters of Health Science at Duke University. Dr. Inrig holds a B.A. from California State University, Sacramento.

    Inducement Awards

    In connection with the hiring of Dr. Inrig, the Compensation Committee of Travere's Board of Directors approved the grant of the following inducement awards to Dr. Inrig, with an effective grant date of January 1, 2022, Dr. Inrig's first date of employment: (i) a stock option to purchase 80,000 shares of Travere common stock, and (ii) a time-based restricted stock unit award covering 20,000 shares of Travere common stock. The stock option has an exercise price per share equal to the closing price of Travere's common stock on January 3, 2022, the first trading day following the date of grant. The stock option is a non-qualified stock option, has a 10-year term and will vest over four years, with one-fourth vesting on the one-year anniversary of the grant date and remaining three-fourths vesting over the following three years in equal monthly installments. The time-based restricted stock unit award will vest over four years, with one-fourth vesting on each anniversary of the grant date.

    Each of the stock awards described above is subject to the terms of Travere's 2018 Equity Incentive Plan, as amended, but was granted outside of the 2018 Equity Incentive Plan, and was granted as an inducement material to Dr. Inrig entering into employment with Travere in accordance with Nasdaq Listing Rule 5635(c)(4).

    About Travere Therapeutics

    At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company that comes together every day to help patients, families and caregivers of all backgrounds as they navigate life with a rare disease. On this path, we know the need for treatment options is urgent – that is why our global team works with the rare disease community to identify, develop and deliver life-changing therapies. In pursuit of this mission, we continuously seek to understand the diverse perspectives of rare patients and to courageously forge new paths to make a difference in their lives and provide hope – today and tomorrow. For more information, visit travere.com

    Forward Looking Statements

    This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. Without limiting the foregoing, these statements are often identified by the words "may", "might", "believes", "thinks", "anticipates", "plans", "expects", "intends" or similar expressions. In addition, expressions of our strategies, intentions or plans are also forward-looking statements. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with the regulatory review and approval process, including the Subpart H accelerated approval pathway. Specifically, the Company faces the risk that sparsentan will not be approved for efficacy, safety, regulatory or other reasons, and for each of the Company's programs, risk associated with enrollment of clinical trials for rare diseases and risk that ongoing or planned clinical trials may not succeed or may be delayed for safety, regulatory or other reasons. The Company faces risk that it will be unable to raise additional funding that may be required to complete development of any or all of its product candidates; risk relating to the Company's dependence on contractors for clinical drug supply and commercial manufacturing; uncertainties relating to patent protection and exclusivity periods and intellectual property rights of third parties; risks associated with regulatory interactions; risks and uncertainties relating to competitive products, including current and potential future generic competition with certain of the Company's products, and technological changes that may limit demand for the Company's products. The Company faces additional risks associated with the potential impacts the COVID-19 pandemic may have on its business, including, but not limited to (i) the Company's ability to continue its ongoing development activities and clinical trials, (ii) the timing of such clinical trials and the release of data from those trials, (iii) the Company's and its suppliers' ability to successfully manufacture its commercial products and product candidates, and (iv) the market for and sales of its commercial products. You are cautioned not to place undue reliance on these forward-looking statements as there are important factors that could cause actual results to differ materially from those in forward-looking statements, many of which are beyond our control. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Investors are referred to the full discussion of risks and uncertainties as included in the Company's most recent Form 10-K, Form 10-Q and other filings with the Securities and Exchange Commission.

    Contact:

    Chris Cline, CFA                                 

    Senior Vice President, Investor Relations & Corporate Communications

    888-969-7879                                        

    [email protected] 



    Primary Logo

    Get the next $TVTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TVTX

    DatePrice TargetRatingAnalyst
    6/11/2025$30.00Buy
    H.C. Wainwright
    6/11/2025$35.00 → $32.00Buy
    Citigroup
    1/10/2025Overweight
    Cantor Fitzgerald
    10/21/2024$9.00 → $27.00Equal Weight → Overweight
    Wells Fargo
    10/16/2024Sector Outperform
    Scotiabank
    9/9/2024$25.00Neutral → Buy
    Guggenheim
    3/27/2024Buy → Neutral
    Guggenheim
    12/5/2023$7.00 → $10.00Neutral → Buy
    Citigroup
    More analyst ratings

    $TVTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright resumed coverage on Travere Therapeutics with a new price target

      H.C. Wainwright resumed coverage of Travere Therapeutics with a rating of Buy and set a new price target of $30.00

      6/11/25 7:55:49 AM ET
      $TVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Citigroup reiterated coverage on Travere Therapeutics with a new price target

      Citigroup reiterated coverage of Travere Therapeutics with a rating of Buy and set a new price target of $32.00 from $35.00 previously

      6/11/25 7:31:38 AM ET
      $TVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald initiated coverage on Travere Therapeutics

      Cantor Fitzgerald initiated coverage of Travere Therapeutics with a rating of Overweight

      1/10/25 9:14:01 AM ET
      $TVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TVTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced that on June 10, 2025, the Compensation Committee of its Board of Directors granted inducement equity grants to 15 new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 81,100 shares of its common stock. These inducement RSUs are subject to the terms of Travere's 2018 Equity Incentive Plan ("2018 Plan") but were granted outside of the 2018 Plan and were granted as inducements material to the new employees entering into employment with Travere in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs vest over four years, with 25% of the shares vesting on each anniversary of the grant dat

      6/12/25 5:00:00 PM ET
      $TVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the 15th International Podocyte Conference

      New data from Phase 2 SPARTAN Study show antifibrotic and anti-inflammatory action of FILSPARI and its impact on B cell and complement pathways in IgAN Travere Therapeutics, Inc., (NASDAQ:TVTX) today announced that the Company will present three abstracts on the effect of FILSPARI (sparsentan) in rare kidney disease at the upcoming International Podocyte Conference in Hamburg, Germany, June 10-13, 2025. The Company will present new data evaluating biomarkers of disease progression in IgA nephropathy (IgAN) from the Phase 2 SPARTAN Study showing rapid and sustained reductions in urinary BAFF and sC5b9 as well as reductions in proinflammatory and profibrotic biomarkers after starting FILS

      6/11/25 7:01:00 AM ET
      $TVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Travere Therapeutics Launches "Play It Forward" Campaign to Celebrate the FSGS Community on Inaugural Awareness Day

      Grammy-winning producer and platinum recording artist joins forces with patient advocate and singer-songwriter to transform the invisible struggle of FSGS into a creative movement New campaign aims to unite the FSGS community and inspire patients and caregivers to share their journeys Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced the launch of a new awareness campaign, "Play It Forward," to bring hope and encouragement to the focal segmental glomerulosclerosis (FSGS) community. FSGS is a rare kidney disease (RKD) affecting children and adults and a leading cause of kidney failure. This press release features multimedia. View the full release here: https://www.businesswire.co

      6/10/25 7:00:00 AM ET
      $TVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TVTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CHIEF MEDICAL OFFICER Inrig Jula sold $11,940 worth of shares (815 units at $14.65), decreasing direct ownership by 0.91% to 88,787 units (SEC Form 4)

      4 - Travere Therapeutics, Inc. (0001438533) (Issuer)

      7/2/25 5:28:57 PM ET
      $TVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Williams Brinkley Ruth was granted 6,500 shares, increasing direct ownership by 34% to 25,750 units (SEC Form 4)

      4 - Travere Therapeutics, Inc. (0001438533) (Issuer)

      5/16/25 7:00:22 PM ET
      $TVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Poole Sandra was granted 6,500 shares, increasing direct ownership by 28% to 30,000 units (SEC Form 4)

      4 - Travere Therapeutics, Inc. (0001438533) (Issuer)

      5/16/25 7:00:18 PM ET
      $TVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TVTX
    SEC Filings

    See more
    • SEC Form S-8 filed by Travere Therapeutics Inc.

      S-8 - Travere Therapeutics, Inc. (0001438533) (Filer)

      6/17/25 5:11:56 PM ET
      $TVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Travere Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - Travere Therapeutics, Inc. (0001438533) (Filer)

      5/16/25 4:13:55 PM ET
      $TVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Travere Therapeutics Inc. filed SEC Form 8-K: Other Events

      8-K - Travere Therapeutics, Inc. (0001438533) (Filer)

      5/15/25 4:29:26 PM ET
      $TVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TVTX
    Leadership Updates

    Live Leadership Updates

    See more
    • Meissa Vaccines Appoints Frank Glavin Chief Executive Officer

      Meissa Vaccines ("Meissa"), a clinical-stage biotechnology company developing vaccines to prevent viral respiratory infections, today announced the appointment of Frank Glavin as Chief Executive Officer, bringing more than 20 years of biotech and pharma experience across the biotech value chain from early-stage research through to commercial planning and business development. Martin Moore, Ph.D., cofounder of Meissa, will serve as the Company's Chief Scientific Officer. "I am excited to welcome Frank to the Meissa leadership team," said Dr. Moore. "We are at an important stage in Meissa's growth, and Frank brings extensive, complementary experience in commercial planning, business developm

      7/11/22 8:00:00 AM ET
      $TVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Eikon Therapeutics Announces the Appointment of Dr. Roy D. Baynes as Executive Vice President and Chief Medical Officer

      Eikon Therapeutics, Inc., a California-based biotechnology company that applies advanced engineering and high-performance computing to the identification of important new medicines, today announced the appointment of Roy D. Baynes, MB, BCh, MMed, PhD, as Executive Vice President and Chief Medical Officer, effective July 11, 2022. A gifted physician-scientist and leading oncologist, Dr. Baynes is among the most experienced – and most successful – clinical development leaders in the biopharmaceutical industry. Dr. Baynes will serve as a consultant to Eikon Therapeutics beginning April 1, 2022 before transitioning to his full-time role as Executive Vice President and Chief Medical Officer in J

      3/23/22 7:30:00 AM ET
      $ATRA
      $NTRA
      $TVTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Medical Specialities
      Biotechnology: Pharmaceutical Preparations
    • Travere Therapeutics Appoints Jula Inrig, M.D., as Chief Medical Officer

      SAN DIEGO, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced the appointment of Jula Inrig, M.D., as chief medical officer, effective immediately. Dr. Inrig brings to Travere more than 15 years of expertise in medical oversight, drug development, clinical trial planning and execution and global regulatory engagement. Dr. Inrig joins the Company as it prepares for accelerated approval submissions of sparsentan for IgA nephropathy (IgAN) and focal segmental glomerulosclerosis (FSGS) in 2022, as well as the continued advancement of its pegtibatinase program in classical homocystinuria (HCU). "We are excited to welcome Jula to the Travere Therapeutics

      1/4/22 4:30:00 PM ET
      $TVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TVTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Travere Therapeutics Inc.

      SC 13G/A - Travere Therapeutics, Inc. (0001438533) (Subject)

      11/14/24 5:13:38 PM ET
      $TVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Travere Therapeutics Inc.

      SC 13G - Travere Therapeutics, Inc. (0001438533) (Subject)

      11/14/24 1:01:01 PM ET
      $TVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Travere Therapeutics Inc.

      SC 13G/A - Travere Therapeutics, Inc. (0001438533) (Subject)

      11/14/24 9:46:28 AM ET
      $TVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TVTX
    Financials

    Live finance-specific insights

    See more
    • Travere Therapeutics Reports First Quarter 2025 Financial Results

      Submitted sNDA seeking full approval of FILSPARI® (sparsentan) for FSGS in March 2025 U.S. net product sales of FILSPARI totaled $55.9 million in 1Q 2025; 703 new PSFs received in the period FILSPARI was recently converted to full approval for the treatment of IgAN in Europe and the UK Clinical data presented at the National Kidney Foundation Spring Clinical Meetings reinforced FILSPARI's foundational position in IgAN and potential in FSGS Cash, cash equivalents, and marketable securities as of March 31, 2025, totaled $322 million Travere Therapeutics, Inc. (NASDAQ:TVTX) today reported its first quarter 2025 financial results and provided a corporate update. "As the only fully approve

      5/1/25 4:01:00 PM ET
      $TVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Travere Therapeutics to Report First Quarter 2025 Financial Results

      Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced it will report first quarter 2025 financial results on Thursday, May 1, 2025, after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET. The webcast and dial-in information can be accessed on the Investor page of Travere's website at https://ir.travere.com/events-and-presentations. Following the live webcast, an archived version of the call will be available for 30 days on the Company's website. About Travere Therapeutics At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company

      4/24/25 4:30:00 PM ET
      $TVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Travere Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results

      SAN DIEGO, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced it will report fourth quarter and full year 2024 financial results on Thursday, February 20, 2025, after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET. The webcast and dial-in information can be accessed on the Investor page of Travere's website at ir.travere.com/events-presentations. Following the live webcast, an archived version of the call will be available for 30 days on the Company's website. About Travere Therapeutics At Travere Therapeutics,

      2/13/25 4:30:00 PM ET
      $TVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care